News Takeda to sell European OTC business to cut debts Japan’s Takeda has said it would sell up to $670 million of over-the-counter (OTC) drug operations in Europe to cut its debts.
News Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
